Proteomic analysis to find predictive markers for chemotherapeutic response, and basic study for biomarker development

为了改善癌症治疗的结果，迫切需要化疗反应的预测标记物。我们先前发现，细胞内S100A10有望成为治疗结直肠癌(CRC)的关键药物奥沙利铂(Oxaliplatin)疗效的候选预测标志之一。在本研究中，我们通过结直肠癌细胞证明，S100A10对L-OHP比5-氟尿嘧啶具有更高的特异性，并提示S100A10与其结合伙伴膜联蛋白A2的相互作用可能参与了耐药的发生。

Predictive markers for chemotherapeutic response are urgently needed to improve the outcomes of cancer treatment. We have previously found that intracellular S100A10 is expected to be one of the candidate predictive markers for response to oxaliplatin, a key drug for the treatment of colorectal cancer(CRC). In this study, we have demonstrated, by using CRC cells, that S100A10 is more specific to L-OHP than 5-fluorouracil and suggested the possibility that the interaction of S100A10 and annexin A2, the binding partner of S100A10, is potentially involved in the chemoresistance.